NAT2 and chronic myelogenous leukemia, BCR-ABL1 positive: From NAT2 G590A samples, 590GG and 590AA genotype distribution was higher among CML patients (29.5%) and (11.5%) respectively, compared to control group (23.0%) and (10.0%).